AusBiotech

Australia’s life sciences sector is growing rapidly, fuelled by pioneering science and the capital needed to take ideas from research to commercialisation.

CSL reported strong profit growth for the past year, but has launched several strategic initiatives, including separating its vaccine business into a standalone company and reducing the number of plasma collection centres in the US.

LTR Pharma said that the publication provides independent validation of SPONTAN's differentiated profile, showing peak plasma concentrations in approximately 10 minutes versus 45 minutes for conventional oral tablets.

Invion (ASX:IVX) has announced that the US FDA has granted orphan drug designation to INV043 for the treatment of anal cancer.

Neurizon Therapeutics (ASX:NUZ) has reported positive topline results from the Open-Label Extension study of its lead candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, which is the primary form of motor neurone disease.

Lucia Bio has announced that it has raised an additional $2 million in seed financing, bringing the total seed investment secured to date to $3 million.

Brandon BioCatalyst, a collaboration of more than 50 of Australia and New Zealand’s leading medical research institutes, hospitals and universities, today announced new board appointments.

Momentum Clinical Research and Pacific Clinical Research Network are merging to form Australasia’s largest, most integrated clinical trial network that can provide delivery capability from Phase 1 first-in-human to Phase 4 clinical trials.

“Her pioneering work in human metabolism and diabetes laid the foundations for Novo Nordisk’s commitment to improving the lives of people with serious chronic diseases through science,” said the company's Dr Ana Svensson.

EMVision Medical Devices (ASX:EMV) has secured a significant boost in its mission to transform stroke care, with the Australian Government awarding the company $3 million in non-dilutive funding under the Cooperative Research Centres Projects Round 17 grant program.

The US FDA has informed Neurizon Therapeutics (ASX:NUZ) that a decision on its Clinical Hold Complete Response for the company's lead investigational therapy NUZ-001 is now not expected until 3 October 2025.

“We showed very clearly that if you brush the cobwebs off, the gene comes on,” said Professor Merlin Crossley, UNSW’s Deputy Vice-Chancellor Academic Quality. “And when we added the methyl groups back, the gene turned off again. So these aren’t cobwebs — they’re anchors.”